NDMA pyrilamine protocols:
In a May 31 letter to FDA, NDMA announces that it expects the results of two studies on the effectiveness of pyrilamine as a menstrual remedy ingredient to be available by early 1992, and requests an "early feedback meeting" to discuss "the specific details of the data analysis as outlined in the protocol, the manner of presentation of the data, additional analysis that might be undertaken and the general format of the submission." On behalf of Chattem and Sterling Drug's Glenbrook OTC division, NDMA has discussed protocol designs for pyrilamine studies in several past feedback meetings. The active ingredient is used in Chattem's Pamprin and Glenbrook's Midol. Pyrilamine was moved from Category I to Category III in the OTC Menstrual Products Tentative Final Monograph published in November 1988.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth